Establishment Labs Holdings Inc. (ESTA) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with double-digit growth in Latin America and a 27% growth in European direct markets. Despite challenges in China, the U.S. market shows good growth and market share gains. Positive guidance for U.S. revenues and strategic focus on account expansion and utilization suggest a positive outlook. The Q&A session confirms strong U.S. growth, premium pricing, and effective inventory strategies, though some uncertainties remain regarding China. Given the company's small-cap status, the stock is likely to react positively in the short term.
Key Financial Performance
Revenue Revenue in the second quarter totaled $51.3 million, a growth of 16% over last year. Excluding the positive impact of foreign exchange, growth would have been approximately 14.3% versus a year ago. Reasons for growth include higher margin sales in the United States and strong performance in direct markets.
U.S. Revenue Second quarter sales in the United States were $10.3 million, exceeding the $9.5 million to $10 million range provided earlier. U.S. revenue is expected to exceed $40 million for the year. Growth is attributed to the superior product benefits of Motiva and successful account acquisition.
European Direct Market Sales Sales in European direct markets increased by approximately 27% this quarter, excluding the benefit of currency and the acquisition of the Benelux distributor. Growth reflects a new sales record and improved operational processes.
Gross Profit Gross profit for the second quarter was $35.3 million or 68.8% of revenue, a 320 basis point increase compared to the 65.6% of revenue for the same period in 2024. The increase reflects higher margin sales in the United States.
Adjusted EBITDA Adjusted EBITDA loss for the quarter was $8.5 million, an improvement from the $12.1 million in the first quarter. The improvement is due to better operating profitability and reduced expenses.
Cash Use Cash use fell to $14.5 million from $21.2 million last quarter. The reduction is attributed to improved cash flow management and operational efficiencies.
Operating Expenses Total operating expenses for the second quarter increased by approximately $11.1 million from the year-ago period to $49.4 million. The increase was primarily due to the ramp-up of commercial activity in the United States, including the Megan Trainer campaign and higher shipping costs.
Latin American Distributors Latin American distributors grew double digits in the second quarter. Stabilization in Brazil and strong growth in Argentina contributed to this performance.
Asia Pacific Sales Asia Pacific sales were 15% of total sales. While there was sequential growth, results were down year-over-year, mostly due to challenges in China and timing of orders from other distributors.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Motiva Flora SmoothSilk Tissue Expander: Won both the Innovation and the Safety Awards in the 2025 Medical Device Network Excellence Awards, establishing it as a benchmark in breast reconstructive surgery.
Preservé: An advanced, less invasive breast enhancement technique designed to preserve natural breast tissue functionality, including nipple sensation and chest muscles. It provides fast post-procedure recovery and is expected to launch in the U.S. in the first half of 2026.
Motiva implants: Clear benefits in breast procedures, especially with smaller implants and prefectoral positions. Expanded range of sizes expected to be FDA-approved in early 2026.
U.S. Market: Revenue in Q2 totaled $10.3 million, exceeding expectations. U.S. revenue is expected to exceed $40 million in 2025. The company has reached over 1,000 accounts in the U.S., with significant growth potential.
European Direct Markets: Sales increased by approximately 27% in Q2, driven by key markets like the U.K., Spain, and Germany.
Latin America: Stabilization in Brazil and strong growth in Argentina. Latin American distributors grew double digits in Q2.
China: Facing challenges but remains a focus area. Motiva is the leading implant across Asia, with plans to achieve the same position in China.
Profitability and Cash Flow: Adjusted EBITDA loss improved to $8.5 million in Q2 from $12.1 million in Q1. Cash use reduced to $14.5 million from $21.2 million last quarter. The company expects its first positive EBITDA quarter later this year and aims for cash flow breakeven in 2026.
Operational Efficiency: Restructured OUS organization, reallocated resources, and applied improved operational processes, leading to benefits in direct markets.
Minimally Invasive Portfolio: Focus on areas with the most financial potential, such as the U.S. and minimally invasive products, while reducing expenses in other areas.
Digital and Social Media Strategy: Leveraging platforms like Instagram and TikTok to attract surgeons and patients, resulting in increased demand for Motiva implants.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
China market challenges: China has been affected by a number of factors, and the company is working with its distribution partner and their investor to ensure success in the region. This indicates operational and market-specific challenges in China.
Cash flow and profitability: The company is currently operating at a loss, with an adjusted EBITDA loss of $8.5 million for the quarter. Although there is improvement, the company is still working towards achieving positive EBITDA later this year and cash flow breakeven by 2026.
Shipping and operational costs: Higher shipping costs, including air shipments to match demand and last-mile shipping costs in the U.S., have increased operational expenses. This could impact profitability if not managed effectively.
Regulatory and market approval: The company is awaiting FDA approval for an expanded range of sizes and breast reconstruction indications, which are critical for future growth. Delays or issues in regulatory approval could hinder strategic objectives.
Economic and market-specific risks: The company faces economic uncertainties in regions like Latin America, where stabilization efforts are ongoing in Brazil, and growth is dependent on market-specific factors.
Competitive pressures: The company is heavily reliant on surgeon adoption of Motiva implants, which involves a gradual process. Competitive pressures from other implant providers could slow down market penetration.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company has raised its revenue guidance for 2025 to a range of $208 million to $212 million, representing growth of 25% to 28%. This includes an expectation of at least $40 million in U.S. Motiva sales and single-digit growth outside the United States.
Sequential Growth Expectation: The company expects sequential growth in the third quarter of 2025, despite the traditional Q3 lull in plastic surgeries.
Profitability and Cash Flow: The company expects its first positive EBITDA quarter later in 2025 and remains on track to achieve cash flow breakeven in 2026. Cash use is expected to reduce by approximately $5 million per quarter for the next several quarters.
U.S. Market Growth: The U.S. market is expected to be the primary engine of growth in 2025, with higher surgeon utilization and the addition of accounts driving growth into 2026. Approval of additional sizes in early 2026 is expected to further accelerate growth.
Preservé Launch: The Preservé procedure is expected to launch in the U.S. in the first half of 2026, commanding a premium price and contributing to gross margin expansion and TAM growth.
Innovation Pipeline: The company plans to bring a cycle of innovation to the U.S. market over the next few years, including minimally invasive procedures and advancements in breast reconstruction.
Global Market Trends: Growth in direct markets outside the U.S. is expected to continue, with European direct markets growing approximately 27% in Q2 2025. Preservé and Mia are expected to contribute meaningfully to growth in international markets.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide more details around the assumptions baked into the revenue guidance upgrade, particularly regarding U.S. Motiva revenues and international sales?
A:The U.S. Motiva revenues are expected to reach at least $40 million, driven by strong surgeon adoption and utilization. European direct markets showed a 27% growth on an underlying basis. However, challenges in China have led to its exclusion from the second-half guidance due to market environment issues and distributor scaling challenges.
Q:Is it fair to assume an acceleration or inflection in growth trajectory as utilization builds and surgeons work through their order books?
A:The growth trajectory is expected to continue gradually rather than experiencing a hockey stick inflection. Growth will come from adding new accounts and increasing adoption in existing accounts.
Q:What does the trajectory of physician adds in the U.S. look like, and when will it shift to a penetration story rather than new site additions?
A:The company continues to add accounts, having reached 1,000 accounts. The focus is shifting towards enhancing utilization rates in existing accounts, though there are still opportunities for new site additions as the sales force expands.
Q:What is the state of the U.S. breast augmentation market, and how is it performing compared to competitors?
A:The U.S. breast augmentation market is showing good growth, with no slowdown observed. The company is gaining market share and driving interest through social media campaigns. Competitors have reported some consumer pressure, but this is not reflected in Motiva's numbers.
Q:How much revenue was impacted by shipping delays in APAC?
A:There was no significant revenue impact from shipping delays. Higher shipping costs were incurred due to air freight usage, but the quantification of the impact is marginal and more of a timing issue.
Q:Are you able to sustain premium pricing for your implants, and what is the competitive response?
A:The company has sustained premium pricing due to the superior product quality. There has been no significant pricing pressure or major coordinated competitive response.
Q:What is the expected cadence of growth for U.S. and global revenues for the rest of the year?
A:Sequential growth is expected in the U.S. in Q3 despite seasonal slowness, with a stronger Q4. Global revenues will also see a step-up in Q4, with the guidance for U.S. revenues at least $40 million being conservative.
Q:Why did SG&A expenses come in higher, and what is the outlook for operating expenses?
A:Higher SG&A expenses were due to increased shipping costs and marketing activities. Operating expenses are expected to trend down in the second half, with leverage coming from higher U.S. revenues.
Q:What is the status of the $50 million investment in the China distributor?
A:The company does not have perfect visibility into the investment but notes that the distributor is facing challenges in scaling commercial operations, leading to slower-than-expected progress.
Q:What is the difference between Mia and Preservé, and which is expected to be larger in the future?
A:Mia is for specific procedures and patients, while Preservé is broader and suitable for everyday use. Preservé is expected to be larger in the future due to its broader applicability.
Q:How is the initiative to place permanent consignment inventory at large customers progressing?
A:The initiative is going well, with over 100 accounts having permanent consignment inventory. This has enhanced utilization rates and improved product availability.
Q:What is the status of the U.S. sales force expansion?
A:The U.S. sales force currently has 43 reps, with plans to add 10-15 reps and management roles in preparation for the Preservé launch.
Q:Can Preservé drive increased adoption and utilization of Mia, and is Preservé included in the 2025 U.S. Motiva revenue guidance?
A:Preservé and Mia are complementary, and Preservé could drive interest in Mia. Preservé is not expected to significantly impact 2025 U.S. Motiva revenue guidance, as its contribution will be minimal.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the $50 million investment in the China distributor, citing a lack of visibility. Additionally, they did not quantify the impact of shipping delays in APAC, describing it as marginal and a timing issue.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
LLC
Research Division
Sales
States basis
acquisition
area improvement
breast augmentation
cash use
competitor
consultation
digit region
effort
example
group surgeon
implant surgeon
improvement cash
industry leader
number account
patient
platform
podium
point increase
practice industry
progress
sale United
sale digit
shipping
sign
surgeon implant
surgeon practice
surgery
timing order
trajectory
trend
use quarter
utilization surgeon
volume practice
ESTA Transcript
Establishment Labs Holdings Inc. (ESTA) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call reveals strong financial performance with a 25% revenue increase and a significant improvement in gross margin to 70%. The company turned a net loss into a net income, and operating cash flow rose by 50%. These positive financial metrics, coupled with the anticipation of future growth and product launches, suggest a positive sentiment. However, the absence of strategic and operational updates, along with management's caution on risks, tempers expectations slightly. Given the company's small-cap status, the stock is likely to see a positive movement of 2% to 8%.
Establishment Labs Holdings Inc. (ESTA) Q4 2025 Earnings Call Transcript
Positive2-24
The earnings call and Q&A reveal strong growth prospects, particularly in the U.S. market and minimally invasive segment, with raised guidance and strategic expansions. The optimism around Preserve and U.S. market penetration, coupled with improved margins and cash flow projections, supports a positive sentiment. However, some uncertainties in management's responses and lack of specific timelines slightly temper expectations, preventing a 'Strong positive' rating. Given the company's market cap, these factors suggest a likely positive stock movement of 2% to 8% in the short term.
Establishment Labs Holdings Inc. (ESTA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Establishment Labs Holdings Inc. (ESTA) Q3 2025 Earnings Call Transcript
Positive11-5
The earnings call highlights strong financial performance with record high revenue, positive EBITDA, and increased cash position. The company raised its revenue guidance and expects continued growth in the U.S. and international markets. The Q&A session confirmed positive momentum, strong market share goals, and strategic expansions. Despite some uncertainties, the overall sentiment is very positive, especially with significant growth expectations and strategic initiatives in place. Given the company's small-cap status, a strong positive stock price reaction is anticipated.
ESTA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
